Treatment of Kawasaki Disease in Suspected or Diagnosed Macrophage Activation Syndrome
Acute Kawasaki disease (KD) presenting alongside suspected or diagnosed macrophage activation syndrome (MAS) requires simultaneous management of both conditions. Current evidence strongly recommends treating KD and MAS concurrently rather than sequentially.
Clinical Scenario
MAS should be suspected in KD patients who present with persistent fever, splenomegaly, markedly elevated ferritin levels, and thrombocytopenia. When MAS is suspected or confirmed in this setting, a combined treatment strategy addressing both KD and the MAS component is indicated.
Treatment Approach — partial overview
The evidence-based regimen centres on intravenous immunoglobulin (IVIG) as the primary intervention for KD, combined with additional targeted agents to address the MAS component and cytokine dysregulation.
Specific agents, sequencing, dosing, and the complete regimen are available in the full structured protocol below.
Treatment Goals
- Resolution of fever
- Resolution of thrombocytopenia
- Normalisation of elevated ferritin levels
- Resolution of splenomegaly
References
DOI: 10.1002/art.42041
- For patients with acute KD and suspected or diagnosed macrophage activation syndrome (MAS), treatment with IVIG for KD and additional agents to treat MAS is strongly recommended.
- KD should be treated with IVIG as the first-line therapy, and MAS should also be treated with appropriate agents for targeting cytokine storm or underlying triggers.
- MAS may be suspected in KD patients with persistent fever, splenomegaly, elevated ferritin levels, and thrombocytopenia.
View source ↗